A New Defense Against a Common Drug’s Deadly Betrayal

PONTE VEDRA, FL – June 24, 2026 – In the intricate systems of modern medicine, trust is the ultimate currency. We trust a simple injection to prevent a life-threatening clot; we trust the systems of science to vet the tools we rely on. But what happens when that trust is broken, when a ubiquitous, life-saving drug turns on the body it’s meant to protect? This is the dangerous paradox of heparin, and it is at the center of a significant development from Cadrenal Therapeutics, a biopharmaceutical company that may be on the verge of providing an answer.

The company announced that data from its Phase 2 study of a new drug, CAD-1005, has been granted a prestigious late-breaking oral presentation at the upcoming 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Paris. For a condition as severe and misunderstood as Heparin-Induced Thrombocytopenia (HIT), this is more than a corporate milestone; it’s a beacon of hope flashed on the world’s most important stage for blood disorders.

The Paradox of Heparin and a Hidden Danger

Heparin is the most widely used blood thinner in hospitals, a cornerstone of treatment and prevention for blood clots in millions of patients undergoing surgery, dialysis, or treatment for heart conditions. Yet, for a small but significant percentage of these individuals, heparin triggers a catastrophic betrayal. The body’s immune system misidentifies the heparin combined with a platelet protein as a threat, launching a full-scale assault.

This reaction, known as Heparin-Induced Thrombocytopenia (HIT), creates a cascade of chaos. The immune response activates platelets, the very cells responsible for clotting, causing them to clump together. This leads to a sharp drop in platelet count (thrombocytopenia) while paradoxically creating new, life-threatening blood clots (thrombosis) in arteries and veins. Patients are left in a perilous state, at high risk for stroke, heart attack, or limb loss. Current management involves stopping heparin and administering alternative anticoagulants, but these therapies are a blunt instrument. They reduce the risk of further clotting but do nothing to address the underlying immune attack that fuels the fire. The storm inside the patient's bloodstream rages on, and the risk of new thrombosis remains alarmingly high.

This gap in care represents a profound unmet need. For decades, clinicians have lacked a targeted therapy to shut down the specific immune mechanism of HIT. The selection of Cadrenal’s study for a presentation at ISTH suggests a potential breakthrough may finally be on the horizon.

Targeting the Betrayal at its Source

Cadrenal’s investigational drug, CAD-1005, represents a fundamental shift in strategy. Instead of merely managing the downstream consequences, it aims to intervene at the root of the problem. As a first-in-class inhibitor of an enzyme called 12-lipoxygenase (12-LOX), CAD-1005 is designed to block the specific signaling pathway that drives the immune-mediated platelet activation in HIT. It’s the difference between bailing water out of a flooding boat and patching the hole that’s letting the water in.

“Targeting 12-lipoxygenase is a novel, highly selective therapeutic approach that addresses the root cause of immune-mediated platelet activation in HIT,” said Dr. Steve McKenzie, the study's principal investigator and a Professor of Medicine at Thomas Jefferson University, who will present the findings in Paris. The data comes from the first-ever randomized, blinded, placebo-controlled trial conducted in HIT patients—a gold standard of clinical research that has been historically difficult to achieve for this acute and complex condition. This level of scientific rigor is critical for building trust in a new therapeutic approach.

Dr. McKenzie noted the potential for a paradigm shift, stating, “The data we are presenting live in Paris... illustrate how CAD-1005 could fundamentally shift the treatment paradigm for acute thrombotic care and may, if approved, offer a highly differentiated option for these high-risk patients.” The drug is intended to be used alongside existing anticoagulants, adding a layer of targeted, mechanism-specific defense that has been missing from the physician’s toolkit.

The Crucible of Global Science

The setting for this announcement is as significant as the science itself. The ISTH Congress is the premier global summit for thrombosis and hemostasis experts, a gathering of over 7,000 clinicians and researchers who define the standards of care. To be selected for a 'late-breaking' oral presentation is a mark of exceptional importance. This designation is reserved for research deemed too new and too critical to wait for the next conference cycle, signaling that the findings could have an immediate impact on scientific understanding and clinical practice.

Presenting in this high-profile session provides an unparalleled platform. It places CAD-1005 directly before the key opinion leaders, regulators, and practicing hematologists who will ultimately decide its fate. This system of peer-reviewed presentation is a cornerstone of how the medical community builds consensus and validates innovation. It’s where a promising compound begins its journey from a corporate press release to a trusted therapy.

“The selection of our Phase 2 CAD-1005 study for a late-breakthrough oral presentation at ISTH is another milestone underscoring the scientific integrity and commercial importance of our pipeline,” said Quang X. Pham, CEO of Cadrenal Therapeutics. This moment serves as a powerful validation of the firm's focused scientific strategy.

From Innovation to Patient: A Small Company's Big Bet

For Cadrenal Therapeutics, this moment is pivotal. The company is navigating the high-risk, high-reward landscape of biopharmaceutical development, focusing on late-stage assets for critical conditions. With CAD-1005 now declared “Phase-3 ready,” the firm is poised to embark on the final, most expensive stage of clinical testing required for regulatory approval.

The company is targeting a market it estimates could reach $2 billion in peak annual revenue, a substantial opportunity for a niche but deadly condition. This potential has been recognized by regulatory bodies; CAD-1005 has already received Orphan Drug and Fast Track designations from the U.S. FDA, as well as orphan status in Europe. These designations are designed to incentivize the development of drugs for rare diseases by providing benefits like market exclusivity and expedited review processes, de-risking the path to commercialization.

While CAD-1005 is the lead program, the company’s broader pipeline, which includes tecarfarin for chronic anticoagulation in complex patient populations, suggests a long-term vision for addressing challenging thrombotic conditions. The upcoming presentation in Paris is not just a scientific reveal but a critical catalyst for the company’s future, potentially attracting the partnerships and capital necessary to bring this promising innovation from the global stage to the patient’s bedside.